3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis

MLA

Richard B Warren, et al. “3 Years of Tralokinumab Treatment Provides Long-Term Disease Control as Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis.” SKIN The Journal of Cutaneous Medicine, vol. 6, Nov. 2022, p. s78. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fe5e0b8d06a8c87288c568d42dc5b282&authtype=sso&custid=ns315887.

APA

Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, Emilia Vacko, Melinda Gooderham, Mette Deleuran, Juan Francisco Silvestre, Stefan Weidinger, & Andrew Blauvelt. (2022). 3 years of tralokinumab treatment provides long-term disease control as demonstrated by clinically meaningful outcomes in moderate-to-severe atopic dermatitis. SKIN The Journal of Cutaneous Medicine, 6, s78.

Chicago

Richard B Warren, Kristian Reich, Eric L Simpson, Richard Langley, Antonio Costanzo, Hidehisa Saeki, Peter Almgren, et al. 2022. “3 Years of Tralokinumab Treatment Provides Long-Term Disease Control as Demonstrated by Clinically Meaningful Outcomes in Moderate-to-Severe Atopic Dermatitis.” SKIN The Journal of Cutaneous Medicine 6 (November): s78. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fe5e0b8d06a8c87288c568d42dc5b282&authtype=sso&custid=ns315887.